SRC and myxoid liposarcoma: Moreover, in vitro NF-kB suppression by Casein kinase II inhibitor TBB and Src inhibition using dasatinib decreased cancer cell viability and offered potential therapeutic strategies for myxoid liposarcoma patients with advanced disease [131].